Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)

Mutations in the gene encoding epidermal growth factor receptor (EGFR) family member HER2 (ERBB2) are common in and drive the growth of “HER2-negative” (not ERBB2-amplified) solid tumors but are rare in primary “HER2-positive” (ERBB2-amplified) breast cancer. We analyzed DNA sequencing data from HER...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Sci Signal
Hauptverfasser: Cocco, Emiliano, Carmona, F. Javier, Razavi, Pedram, Won, Helen H., Cai, Yanyan, Rossi, Valentina, Chan, Carmen, Cownie, James, Soong, Joanne, Toska, Eneda, Shifman, Sophie G, Sarotto, Ivana, Savas, Peter, Wick, Michael J., Papadopoulos, Kyriakos P., Moriarty, Alyssa, Cutler, Richard E., Avogadri-Connors, Francesca, Lalani, Alshad S., Bryce, Richard P., Chandarlapaty, Sarat, Hyman, David M., Solit, David B., Boni, Valentina, Loi, Sherene, Baselga, José, Berger, Michael F., Montemurro, Filippo, Scaltriti, Maurizio
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2018
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6498841/
https://ncbi.nlm.nih.gov/pubmed/30301790
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scisignal.aat9773
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge